(Z)-1-(1,3-benzodioxol-5-yl)-3-(2-bromoanilino)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: (Z)-1-(1,3-benzodioxol-5-yl)-3-(2-bromoanilino)prop-2-en-1-one
• 化学式: C₁₆H₁₂BrNO₃
• 分子量: 346.17
• InChiKey: RDSREUCDDPLFPK-FPLPWBNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] ANALOGUES DE 2-AMINOARYL-5-ARYLOXAZOLE DESTINÉS AU TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：SOUTHERN RES INST

  公开号：WO2019164996A1

  公开（公告）日：2019-08-29

  The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-κΒ signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及能够激活NF-κΒ信号通路的2-氨基芳基-5-芳氧唑化合物。本公开还涉及使用这些化合物治疗神经系统疾病的方法，例如肌萎缩侧索硬化症（ALS）、阿尔茨海默病、帕金森病、脊髓性肌萎缩、创伤性脑损伤、血管性痴呆、亨廷顿病、智力障碍以及注意力缺陷和多动症（ADHD），以及神经肌肉疾病，例如杜兴氏肌营养不良（DMD）。本摘要旨在作为在特定领域中搜索的扫描工具，并不意味着对本发明的限制。
• 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Southern Research Institute

  公开号：US20210188791A1

  公开（公告）日：2021-06-24

  The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Southern Research Institute

  公开号：US20210246110A1

  公开（公告）日：2021-08-12

  The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.